"Pharmaceutical Express" AstraZenecon long-acting new coronary antibody began phase III clinical.

October 10, 2020 / Medical Information List: AstraZenetel's long-acting new crown antibody begins Phase III clinical trials; Astellas ADC therapy declares clinical in China; Dabohua ® (Lytoxi monoantigen injections) is officially approved for listing in China; supplies price reduction The largest alliance in the North is coming... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief NMPA Issued guidelines and templates for drug commissioned production quality agreements On October 9, the State Drug Administration issued the Guidelines for Drug Commissioned Production Quality Agreements (2020 edition) to guide and supervise drug market licensees and entrusted production enterprises to fulfill their drug quality assurance obligations.
the Guide shall come into effect as of the date of publication.
(State Drug Administration) supplies price reduction North's largest alliance came on October 9, Shanxi Province, the centralized bidding and procurement center for pharmaceutical equipment issued "on the Beijing-Tianjin-Hebei "3-N" artificial crystal category joint volume procurement of selected products purchase and sale contract signed related work notice."
Recently, according to the official website of Tianjin Pharmaceutical Purchasing Center, "Beijing-Tianjin-Tianjin-Hebei and Heji Liaomun Jinlu Pharmaceutical Joint Purchasing Office" released the results of the proposed joint strip procurement competition for medical supplies (artificial crystals).
(Shanxi Province Pharmaceuticals Centralized Tendering and Procurement Center) Part 2 production through the Hong Kong Stock Exchange hearing in the third quarter has welcomed two key products according to the Announcement of the Hong Kong Stock Exchange, Sonic Pharmaceuticals has recently been heard through the Hong Kong Stock Exchange.
submitted an IPO application on the Hong Kong Stock Exchange in June this year, in accordance with Article 8.12 of the Listing Rules.
according to the hearing information set, the funds raised at HKEx will be used in part for the ongoing research and development of selected products in the field of oncology and the central nervous system.
less than two weeks after the D-round financing, is the new company planning to open up new treatments for fibrosis? Galecto Biotech, based in Copenhagen, Denmark, today announced it had filed for an IPO with NASDAQ to raise $100m, two weeks after completing a $64m round of D-round financing.
(Xinhua) -- Part 3 Drug News Pfizer Ibrance Treatment of Early Breast Cancer Another Phase 3 Clinical Failure Lilly or Advantage On October 9, Pfizer announced that Ibrance has failed in peneLOPE-B, the second major Phase 3 clinical study for the treatment of HR-/HER2-Early Breast Cancer.
(Sina Pharmaceutical News) ALKS 3831 Therapeutic Fine Points and Bipolar Affective Disorders were voted in favour by the FDA Advisory Committee on October 9, Alkermes announced that the FDA-appointed Advisory Committee on Psychopharmaceuticals and Drug Safety and A joint meeting of the Risk Management Advisory Committee gave positive voting results for the treatment of adult schizophrenics and adult type I bipolar disorder patients with oral atypical antipsychotic drug candidate APKS 3831 (otoxypine/samidorphan).
(Sina Pharmaceutical News) Chenxin Pharmaceuticals Esomera omeprazole magnesium intestinal capsule approved by the U.S. FDA on October 9, Chenxin Pharmaceuticals announced that recently received a notice from the U.S. FDA, the company to the U.S. FDA to declare the application for a simple new drug of Esomeraazole magnesium intestinal capsule (Abbreviated NewDruglication, that is, the U.S. generic drug application) has been approved.
(Sina Pharmaceutical News) People's Fu Pharmaceuticals La Bellore tablets obtained FDA approval number today, People's Pharmaceuticals announced that its wholly-owned subsidiary Epic Pharma received FDA approval for hydrochloric acid la bellore tablets.
(Sina Pharmaceutical News) Dabohua® (Lytoxi mono-anti-injection) was officially approved for listing in China today, Lilly Pharmaceuticals and Cynda Biopharmaceuticals jointly announced that the two sides jointly developed a recombinant human-rat-embedded anti-CD20 monoclonal antibody injection Dabohua ® (Lytoxi single anti-injection, English trademark: HALPRYZA®) has been officially approved by the State Drug Administration for the treatment of diffuse large B-cell lymphoma, filthy lymphoma and chronic lymphocytic leukemia.
(Sina Pharmaceutical News) Breakthrough Therapy! Today Astellas submitted a clinical application for ADC therapy was accepted by CDE today CDE publicity, Astellas in China submitted 2 clinical trial applications for injection enfortumab vedotin, and was accepted.
, an antibody-coupled drug (ADC) targeted at Nectin-4 that has been approved by the FDA for breakthrough therapy and priority review, was approved for use in the U.S. at the end of 2019 for the treatment of patients with locally advanced or metastatic urethra cancer.
(Drug Mingkang) AstraZenecon Long-Acting New Coronary Antibodies Begin Phase III Clinical Today AstraZenecon announced that its Long-Acting New Coronary Antibody (LAAB) combination will begin a Phase III clinical trial of prevention for 6,000 people and a Phase III clinical trial for 4,000 people.
the drug, codenamed AZD7442, is a mixture of two antibodies called COV2-2196 and COV2-2130, which bind to two different bits of the new coronary S protein.
(U.S.-China Medicine Source) NEJM published the final results of the Redsivir Global Trials showing three significant benefits after preliminary results of a global clinical trial sponsored by the American Institute of Allergy and Infectious Diseases (NIAID) called ACTT-1 showed that Redsyvirus significantly accelerated the recovery time of patients hospitalized with the new coronavirus disease (COVID-19).
the final report of the ACTT-1 trial was published in the New England Journal of Medicine (NEJM) on October 8.
(Medical New View point)